Switch theme
Sign up to access all valuation multiples
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
2018
1.6K+
LTM Revenue $2.1B
LTM EBITDA $256M
$414M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Frontage Laboratories has a last 12-month revenue (LTM) of $2.1B and a last 12-month EBITDA of $256M.
In the most recent fiscal year, Frontage Laboratories achieved revenue of $32.5M and an EBITDA of $6.4M.
Frontage Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Frontage Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.1B | XXX | $32.5M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $8.9M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $256M | XXX | $6.4M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $99.3M | XXX | $1.2M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $13.8M | XXX | $0.1M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $6.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Frontage Laboratories's stock price is HKD 1 (or $0).
Frontage Laboratories has current market cap of HKD 2.4B (or $304M), and EV of HKD 3.3B (or $414M).
See Frontage Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $414M | $304M | XXX | XXX | XXX | XXX | $0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Frontage Laboratories has market cap of $304M and EV of $414M.
Frontage Laboratories's trades at 12.8x EV/Revenue multiple, and 65.1x EV/EBITDA.
Equity research analysts estimate Frontage Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Frontage Laboratories has a P/E ratio of 173.6x.
See valuation multiples for Frontage Laboratories and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $304M | XXX | $304M | XXX | XXX | XXX |
| EV (current) | $414M | XXX | $414M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBITDA | 12.7x | XXX | 65.1x | XXX | XXX | XXX |
| EV/EBIT | 32.8x | XXX | 348.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 173.6x | XXX | 3018.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 220.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFrontage Laboratories's last 12 month revenue growth is 9%
Frontage Laboratories's revenue per employee in the last FY averaged $21K, while opex per employee averaged $5K for the same period.
Frontage Laboratories's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Frontage Laboratories's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Frontage Laboratories and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 204% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 122% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $21K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $5K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Frontage Laboratories acquired XXX companies to date.
Last acquisition by Frontage Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Frontage Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Frontage Laboratories founded? | Frontage Laboratories was founded in 2018. |
| Where is Frontage Laboratories headquartered? | Frontage Laboratories is headquartered in Hong Kong. |
| How many employees does Frontage Laboratories have? | As of today, Frontage Laboratories has 1.6K+ employees. |
| Is Frontage Laboratories publicy listed? | Yes, Frontage Laboratories is a public company listed on HKG. |
| What is the stock symbol of Frontage Laboratories? | Frontage Laboratories trades under 01521 ticker. |
| When did Frontage Laboratories go public? | Frontage Laboratories went public in 2019. |
| Who are competitors of Frontage Laboratories? | Similar companies to Frontage Laboratories include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Frontage Laboratories? | Frontage Laboratories's current market cap is $304M |
| What is the current revenue of Frontage Laboratories? | Frontage Laboratories's last 12 months revenue is $2.1B. |
| What is the current revenue growth of Frontage Laboratories? | Frontage Laboratories revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Frontage Laboratories? | Current revenue multiple of Frontage Laboratories is 1.6x. |
| Is Frontage Laboratories profitable? | Yes, Frontage Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Frontage Laboratories? | Frontage Laboratories's last 12 months EBITDA is $256M. |
| What is Frontage Laboratories's EBITDA margin? | Frontage Laboratories's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Frontage Laboratories? | Current EBITDA multiple of Frontage Laboratories is 12.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
